Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 6:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 327 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Dacogen Clear all
Recruiting Phase 1 Interventional

Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies

NCT07044544
View directory record Official record
Conditions
Myeloid Malignancy, Hematologic Malignancy, Acute Myeloid Leukemia, Myelodysplastic Syndromes
Interventions
G-CSF, Decitabine, Venetoclax
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 20, 2026, 6:16 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Eltanexor (KPT-8602) With Inqovi (Decitabine-Cedazuridine) in High-Risk Myelodysplastic Syndromes

NCT05918055
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
KPT-8602, Inqovi, Bone marrow aspirate, Bone marrow biopsy, ECG
Drug · Procedure · Diagnostic Test
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Oct 20, 2026, 6:16 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral Cytidine Deaminase Inhibitor (CDAi) in Patients With Myelodysplastic Syndromes (MDS)

NCT02103478
View directory record Official record
Conditions
Myelodysplastic Syndrome, MDS
Interventions
ASTX727 Dose Escalation, ASTX727 Dose Confirmation, ASTX727 Fixed-Dose Combination
Drug
Lead sponsor
Astex Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
13
States / cities
Phoenix, Arizona • Los Angeles, California • Chicago, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2024 · Synced Oct 20, 2026, 6:16 PM EDT
Completed Phase 1 Interventional

Combination of Decitabine and Midostaurin in Patients Older Than 60 With Newly Diagnosed or Relapsed Refractory Acute Myeloid Leukemia

NCT01130662
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
combination therapy using decitabine and midostaurin
Drug
Lead sponsor
University of Kansas
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 26, 2013 · Synced Oct 20, 2026, 6:16 PM EDT
Completed Phase 2 Interventional Results available

Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS

NCT04055844
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myeloid and Monocytic Leukemia, Myelodysplastic Syndromes
Interventions
Decitabine, Ruxolitinib, Donor Lymphocyte Infusion (DLI)
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
12 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
3
States / cities
Minneapolis, Minnesota • St Louis, Missouri • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Oct 20, 2026, 6:16 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Treatment of Resistant Metastatic Melanoma Using Decitabine, Temozolomide and Panobinostat

NCT00925132
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
Temozolomide, Decitabine, Panobinostat
Drug
Lead sponsor
University of Iowa
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 20, 2026, 6:16 PM EDT
Completed Phase 1 Interventional

Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome

NCT05564650
View directory record Official record
Conditions
Myelodysplastic Syndrome, Recurrent Myelodysplastic Syndrome, Refractory Myelodysplastic Syndrome
Interventions
Navitoclax, Venetoclax, Decitabine, Bone Marrow Biopsy, Biospecimen Collection, Laboratory Biomarker Analysis, Quality-of-Life Assessment
Biological · Drug · Procedure + 1 more
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 20, 2026, 6:16 PM EDT
Completed Phase 2 Interventional Results available

Phase II Decitabine (DAC) Versus Azacitidine (AZA) in Myelodysplastic Syndrome (MDS)

NCT02269280
View directory record Official record
Conditions
Leukemia
Interventions
Azacitidine (AZA) Days 1 - 3, Decitabine (DAC), Best Supportive Care (BSC), Azacitidine (AZA) Days 1 - 5
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
6
States / cities
Tampa, Florida • Baltimore, Maryland • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2025 · Synced Oct 20, 2026, 6:16 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

To Study the Oral Bioavailability of a New Combination Formation of Decitabine and Tetrahydrouridine in Healthy Males

NCT05816356
View directory record Official record
Conditions
Healthy
Interventions
Decitabine, Tetrahydrouridine
Drug
Lead sponsor
EpiDestiny, Inc.
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 22, 2025 · Synced Oct 20, 2026, 6:16 PM EDT
Terminated Phase 1 Interventional

Physical Conditioning and Decitabine for Newly Diagnosed AML Patients Age ≥ 60

NCT02234037
View directory record Official record
Conditions
Leukemia
Interventions
Decitabine, Exercise
Drug · Behavioral
Lead sponsor
Emory University
Other
Eligibility
60 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 30, 2017 · Synced Oct 20, 2026, 6:16 PM EDT
Completed Phase 1 Interventional

Decitabine and Bortezomib in Treating Patients With Acute Myeloid Leukemia

NCT00703300
View directory record Official record
Conditions
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Recurrent Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
Interventions
bortezomib, decitabine, pharmacological study, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 7, 2014 · Synced Oct 20, 2026, 6:16 PM EDT
Terminated Phase 1 Interventional

Decitabine With or Without Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Solid Tumors

NCT00701298
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
peginterferon alfa-2b, decitabine, laboratory biomarker analysis
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Feb 24, 2014 · Synced Oct 20, 2026, 6:16 PM EDT
Terminated Phase 1 Interventional

Decitabine in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas

NCT00089089
View directory record Official record
Conditions
Hematopoietic/Lymphoid Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
decitabine, pharmacological study, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 7, 2013 · Synced Oct 20, 2026, 6:16 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Decitabine in Treating Patients With Myelofibrosis

NCT00095784
View directory record Official record
Conditions
Primary Myelofibrosis, Secondary Myelofibrosis
Interventions
Decitabine, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2027
U.S. locations
14
States / cities
Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 20, 2026, 6:16 PM EDT
Terminated Phase 1 Interventional

Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticles as Monotherapy or in Combination in Acute Myeloid Leukemia Participants.

NCT03217838
View directory record Official record
Conditions
Acute Myeloid Leukaemia
Interventions
AZD2811, Azacitidine, Venetoclax
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
10
States / cities
Denver, Colorado • Sarasota, Florida • Detroit, Michigan + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2022 · Synced Oct 20, 2026, 6:16 PM EDT
Active, not recruiting Phase 2 Interventional

Venetoclax and ASTX727 for the Treatment of Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia

NCT04746235
View directory record Official record
Conditions
Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions
Decitabine and Cedazuridine, Venetoclax
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 20, 2026, 6:16 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Phase I/II: Decitabine/Vaccine Therapy in Relapsed/Refractory Pediatric High Grade Gliomas/Medulloblastomas/CNS PNETs

NCT02332889
View directory record Official record
Conditions
Gliomas, Medulloblastoma, Neuroectodermal Tumors, Primitive
Interventions
Vaccine (autologous dendritic cells), Decitabine and Hiltonol
Biological · Drug
Lead sponsor
University of Louisville
Other
Eligibility
2 Years to 25 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated May 4, 2018 · Synced Oct 20, 2026, 6:16 PM EDT
Completed Phase 2 Interventional Results available

Decitabine and Vorinostat Conditioning Followed by CD3-/CD19- NK Cells Infusion for High Risk Myelodysplastic Syndromes

NCT01593670
View directory record Official record
Conditions
Myelodysplastic Syndrome
Interventions
Decitabine, Vorinostat, Interleukin-2, Natural killer (NK) cells
Drug · Biological · Other
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
2
States / cities
Minneapolis, Minnesota • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 21, 2019 · Synced Oct 20, 2026, 6:16 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Phase I/II Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029, an ERK Inhibitor, for Patients With RAS Pathway Mutant Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms

NCT06284460
View directory record Official record
Conditions
Pathway Mutant Myelodysplastic Syndromes, Myelodysplastic Neoplasm, Myeloproliferative Neoplasm
Interventions
ASTX029, ASTX727
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 20, 2026, 6:16 PM EDT
Recruiting Phase 2 Interventional

Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD

NCT06511882
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Azacitidine, Decitabine, Venetoclax
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 20, 2026, 6:16 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Test How Either a Capsule or a Tablet With NDec (Decitabine and Tetrahydrouridine) Works in the Body of Healthy People

NCT06291285
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Decitabine-THU
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 64 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 29, 2025 · Synced Oct 20, 2026, 6:16 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Pembrolizumab and Decitabine for Refractory or Relapsed Acute Myeloid Leukemia

NCT02996474
View directory record Official record
Conditions
Relapsed Acute Myeloid Leukemia
Interventions
Pembrolizumab, Decitabine
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 28, 2022 · Synced Oct 20, 2026, 6:16 PM EDT
Completed Phase 1Phase 2 Interventional

Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes

NCT00075010
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes
Interventions
Decitabine, Valproic acid
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
2 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Oct 20, 2026, 6:16 PM EDT
Completed Phase 2 Interventional

Leukemia SPORE Phase II DAC Study for R/R and Elderly Acute AML and MDS

NCT02190695
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia
Interventions
Decitabine, Carboplatin, Arsenic trioxide
Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 19, 2021 · Synced Oct 20, 2026, 6:16 PM EDT